The Cleveland Clinic Foundation

University of Michigan

Case Western Reserve University

Nima Sharifi

Kai-Hsiung Chang

Zhenfei Li

Richard Auchus

Joe G Zein

The present invention relates to methods, kits, and compositions for testing a sample from a subject with asthma to determine: i) if the subject is A/A or A/C at position 1245 in the HSD3B1 gene, and/or if the subject expresses a 367N version of the 3β-HSD1 protein (e.g., and should be administered a non-corticosteroid for their asthma), or ii) if the subject is C/C at position 1245 in the HSD3B1 gene, and/or if the subject expresses only the 367T version of the 3β-HSD1 protein (e.g., and should be administered a corticosteroid for their asthma). In certain embodiments, the corticosteroid is a glucocorticoid.

Detection for determining corticosteroid responsiveness

Methods and kits for characterizing a subject having a steroid-dependent disease such as prostate cancer are described. A method of treating a steroid-dependent disease in a subject by obtaining a biological sample from the subject, determining if the HSD3B1(1245C) gene or 3&#x3b2;HSD1(367T) protein is expressed in the biological sample, and providing treatment other than or in addition to steroid ablation to the subject if the HSD3B1(1245C) gene or 3&#x3b2;HSD1(367T) protein is expressed is also described.

3.beta-hydroxysteroid dehydrogenase in steroid dependent disease

A method of treating steroid-dependent disease such as prostate cancer in a subject is described that includes administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5-&#x3b1;-reductase inhibitor to the subject.

Altering steroid metabolism for treatment of steroid-dependent disease

Method for treating castration-resistant prostate cancer

Growing community of inventors

Shaker Heights, OH, United States of America

Nima Sharifi